Table 2.
Suggested dosing of combined inhaled corticosteroids and long-acting beta2-agonists (LABAs) for asthma therapy in adults and adolescents (≥ 12 years).
| Combination inhaler | Inhaler type | Dose | Maximum # of daily inhalations (regardless of dose) | ||
|---|---|---|---|---|---|
| Low | Medium | High | |||
| Budesonide/formoterol (Symbicort®) | MDI | 80 mcg/4.5 mcg (2 inh twice daily) | 160 mcg/4.5 mcg (2 inh twice daily) | 4 inh | |
| Fluticasone/salmeterol (Advair®) diskus | DPI | 100 mcg/50 mcg (one inh twice daily) | 250 mcg/50 mcg (one inh twice daily) | 500 mcg/50 mcg (one inh twice daily) | 2 inh |
| Fluticasone/salmeterol (Advair®) HFA | HFA | 45 mcg/21 mcg (2 inh twice daily) | 115 mcg/21 mcg (2 inh twice daily) | 230 mcg/21 mcg (2 inh twice daily) | 4 inh |
| Mometasone/formoterol (Dulera®) | MDI | 100 mcg/5 mcg (2 inh twice daily) | 200 mcg/5 mcg (2 inh twice daily) | 4 inh | |
Abbreviations: inh, inhalation; DPI, dry powder inhaler; HFA, hydrofluoroalkane inhaler; MDI, metered dose inhaler.